DETERMINATION OF TREATMENT RESULTS PRIOR TO TREATMENT OR AFTER FEW TREATMENT EVENTS

• US 20080167571A1
• Filed: 12/14/2007
• Published: 07/10/2008
• Est. Priority Date: 12/19/2006
• Status: Abandoned Application

• Current Assignee: Alan Gevins
• Original Assignee: Alan Gevins
• Inventors: Gevins, Alan
• Application Number:
  US11/957,156
• Publication Number:
  US 20080167571A1
• Time in Patent Office: Days
• US Class Current: 600/544
• CPC Class Codes: A61B 5/377 using evoked responses
• CPC Class Codes: A61B 5/378 Visual stimuli
• CPC Class Codes: A61B 5/38 Acoustic or auditory stimuli
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61N 1/36025 for treating a mental or cerebral condition

Abstract

Disclosed are methods and data on determining response to a drug or other therapy prior to administration by obtaining a direct neurocognitive brain function measurement; obtaining an indirect neurocognitive brain function measurement; and, assessing the direct neurocognitive brain function measurement and the indirect neurocognitive brain function measurement collectively to obtain a response determination preferably the predictive value of the collective assessment is greater than a predictive value obtained from the separate predictive values for the direct and indirect measurements. Also disclosed are methods of determining dosage of a drug comprising administering a drug; comprising obtaining a direct neurocognitive brain function measurement; obtaining an indirect neurocognitive brain function measurement; and, assessing the direct neurocognitive brain function measurement and the indirect neurocognitive brain function measurement collectively to obtain a dosage, preferably the predictive value of the collective assessment is greater than a predictive value obtained from the separate predictive values for the direct and indirect measurements; optionally, additional cycles of obtaining and assessing indirect and direct measurements are performed.

Claims

1. A method of predicting response to a drug prior to drug administration comprising:

obtaining a direct brain function measurement;

obtaining an indirect brain function measurement; and

,

assessing the direct brain function measurement and the indirect brain function measurement collectively to obtain a drug response prediction,

whereby the predictive value of the collective assessment is greater than a predictive value obtained from the separate predictive values for the direct and indirect measurements.

2. The method according to claim 1 wherein the direct brain function measurement and the indirect brain function measurement are selected from an example set forth in Table 3.

3. The method according to claim 1 wherein the direct brain function measurement and the indirect brain function measurement elicit data on the same physiological functions as set forth in an example represented in Table 3.

4. The method according to claim 3 wherein the physiological functions are selected from the group consisting of:

attention regulation, memory, alertness regulation, regulation of other neurocognitive functions, regulation of sensory or motor functions, and regulation of mass neuronal synchronization.

5. A method of determining dosage of a drug with a linear dose-response curve, comprising steps of:

administering a drug;

obtaining a direct brain function measurement;

obtaining an indirect brain function measurement; and

,

assessing the direct brain function measurement and the indirect brain function measurement collectively to obtain a dosage prediction

whereby the predictive value of the collective assessment is greater than a predictive value obtained from the separate predictive values for the direct and indirect measurements.

6. The method according to claim 5, wherein the direct brain function measurement and the indirect brain function measurement are selected from an example set forth in Table 3.

7. The method according to claim 5 wherein the direct brain function measurement and the indirect brain function measurement elicit data on the same physiological functions as set forth in an example represented in Table 3.

8. The method according to claim 7 wherein the physiological functions are selected from the group consisting of:

attention regulation, memory, alertness regulation, regulation of other neurocognitive functions, regulation of sensory or motor functions, and regulation of mass neuronal synchronization.

9. A method of determining dosage of a drug with a nonlinear dose-response curve to achieve a specified response, comprising steps of:

administering a first test dose of the drug;

calculating a dose-response value for the test dose;

subsequently,

administering a second test dose of the drug;

calculating a dose-response value for the second test dose;

calculating the slope between the responses to the two doses;

extrapolating from the slope to a reach a specified response level; and

,

identifying the dose that corresponds to that response level.

10. The method according to claim 9 wherein the indirect measurement is selected from the group consisting of:

information about brain structure, information from genetic measures, information from bodily fluids, information about a patient'"'"'s behavior from task performance data, psychometric data, self-report data, third party assessment and clinical scales.

11. A method of detecting mild cognitive impairment (“

MCI”

), comprising steps of;

obtaining a direct brain function measurement;

obtaining an indirect brain function measurement;

assessing the direct brain function measurement and the indirect brain function measurement collectively to obtain a prediction of the subject'"'"'s brain function

whereby the predictive value of the collective assessment is greater than a predictive value obtained from the separate predictive values for the direct and indirect measurements.

12. The method of claim 11, wherein the step of obtaining an indirect brain function measurement comprises obtaining patient information on genetic marker for Apolipoprotein E and the assessing step comprises assessment of Apolipoprotein E.

13. The method of claim 12, wherein the step of obtaining an indirect brain function measurement comprises obtaining patient information on genetic marker for Apolipoprotein E and at least one other indirect measurement, and the assessing step comprises assessment of Apolipoprotein E and at least one other indirect measurement.

14. The method according to claim 11, wherein the direct brain function measurement and the indirect brain function measurement are selected from an example set forth in Table 3.

15. The method according to claim 11 wherein the direct brain function measurement and the indirect brain function measurement elicit data on the same physiological functions as set forth in an example represented in Table 3.

16. The method according to claim 15 wherein the physiological functions are selected from the group consisting of:

attention regulation, memory, alertness regulation, regulation of other neurocognitive functions, regulation of sensory or motor functions, and regulation of mass neuronal synchronization.